Nanohale AG (ETR:FYB)

BRIEF

published on 02/05/2025 at 06:35, 10 months ago

Lotus Pharmaceutical Partners with Formycon to Commercialize Eylea® Biosimilar in Asia-Pacific

Lotus Pharmaceutical Eylea® Biosimilar Asia-Pacific Commercialization FDA And EU Approval Retinal Disease Treatment
PRESS RELEASE

published on 02/05/2025 at 06:30, 10 months ago

Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
Formycon AG announces strategic partnership with Lotus Pharmaceutical for commercialization of Eylea biosimilar FYB203/AHZANTIVE in Asia-Pacific region

Formycon AG Asia-Pacific Eylea Biosimilar FYB203/AHZANTIVE Lotus Pharmaceutical
BRIEF

published on 01/20/2025 at 06:35, 10 months 16 days ago

Formycon Secures EU Approval for Biosimilar FYB203

Formycon AG EU Approval Teva Pharmaceuticals Aflibercept Biosimilar FYB203
PRESS RELEASE

published on 01/20/2025 at 06:30, 10 months 16 days ago

Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
Formycon receives EU approval for biosimilar FYB203 (aflibercept) to Eylea®, brands AHZANTIVE® and Baiama® for nAMD and retinal diseases. Teva to market AHZANTIVE® in Europe

Biosimilar Formycon EU Approval AHZANTIVE Baiama
BRIEF

published on 01/15/2025 at 06:35, 10 months 21 days ago

MHRA Grants Approval for Formycon and Fresenius Kabi's Otulfi®

Formycon Fresenius Kabi Ustekinumab Biosimilar Approval Otulfi® Launch
PRESS RELEASE

published on 01/15/2025 at 06:30, 10 months 21 days ago

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi®, a biosimilar to Stelara®, for various inflammatory diseases. Global biosimilar approval news

Biosimilar Formycon Fresenius Kabi FYB202 MHRA Approval
BRIEF

published on 01/13/2025 at 07:05, 10 months 23 days ago

Teva Partners with Formycon for FYB203 Biosimilar in Europe and Israel

Biosimilars Formycon Teva FYB203 Europe And Israel
PRESS RELEASE

published on 01/13/2025 at 07:00, 10 months 23 days ago

Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
Teva partners with Formycon for commercialization of biosimilar FYB203 (Eylea®) in Europe and Israel, aiming to expand access to innovative medicines

Biosimilar Formycon Teva FYB203 Eylea
BRIEF

published on 01/09/2025 at 15:35, 10 months 26 days ago

Formycon Joins TecDAX Index

Stock Market Biosimilars Deutsche Börse TecDax Formycon
PRESS RELEASE

published on 01/09/2025 at 15:30, 10 months 26 days ago

Formycon included in TecDAX Index of Deutsche Börse
Formycon AG to be included in TecDAX Index of Deutsche Börse, enhancing visibility and market position. Company specializes in biosimilars for various disease areas

Formycon AG Biosimilars Deutsche Börse TecDAX Index Technology Stocks

Published on 12/05/2025 at 02:35, 6 hours 40 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 6 hours 45 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 8 hours 15 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 10 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 15 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

Published on 12/05/2025 at 09:05, 10 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 14 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 15 minutes ago

SPECTRIS PLC - Removal
Published on 12/05/2025 at 09:00, 15 minutes ago

Official List Notice
Published on 12/05/2025 at 09:00, 15 minutes ago

Petershill Partners plc - Removal

View all EQS

Published on 12/05/2025 at 08:45, 30 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 15 hours 15 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 15 hours 30 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 15 hours 31 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 2 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE

News